Indian Journal of Pharmacology最新文献

{"title":"Microteaching: Overview and examination evaluation.","authors":"Pugazhenthan Thangaraju, Bikash Medhi","doi":"10.4103/ijp.ijp_912_21","DOIUrl":"10.4103/ijp.ijp_912_21","url":null,"abstract":"<p><p>Nearly all teachers are forced into teaching and gain experience through time, but many do not feel adequately prepared for their fieldwork in their training program. Only solution which helps teachers and students is to connect theory to practice by microteaching. It is a strategy for acquiring teaching abilities on a smaller scale, in which teachers may practice previously learned skills as well as acquire new ones. The efficiency of microteaching may be predicted using feedback from participants. While preservice instructors benefit from microteaching and students themselves find it helpful, academics have not yet looked closely at the assignment itself to determine precisely what microteaching entails. As a result, this study aids in learning more about the interactional aspects of microteaching and the effect of it in both teachers and students.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41109039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing the knowledge and interpretation skills of ChatGPT in pharmacology examination of phase II MBBS.","authors":"Anitha Elango, Neevedha Kannan, Isswariya Anandan, Krishna Mohan Surapaneni","doi":"10.4103/ijp.ijp_188_23","DOIUrl":"10.4103/ijp.ijp_188_23","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41122080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixed drug eruption - Experience from a tertiary care center in Uttarakhand.","authors":"Neirita Hazarika, Puneet Dhamija, Amrita Upadhyaya, Manisha Rauthan","doi":"10.4103/ijp.ijp_177_23","DOIUrl":"10.4103/ijp.ijp_177_23","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41109022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of vascular endothelial growth factor in tuberculous meningitis: A prospective study from a tertiary care center in North India.","authors":"Devesh Kumar, Deependra Singh, Tanish Modi, Riya Sharma, Anand Keshav Awasthy, Ritu Shree, Manoj Kumar Goyal, Dhawal Narang, Siddharth Chand, Sameer Vyas, Kusum Sharma, Navneet Sharma, Rudresh Gowda, Abeer Goel, Rajeev Ranjan, Manish Modi","doi":"10.4103/ijp.ijp_743_22","DOIUrl":"10.4103/ijp.ijp_743_22","url":null,"abstract":"<p><strong>Introduction: </strong>The status of vascular endothelial-derived growth factor (VEGF) in the pathogenesis of tuberculous meningitis (TBM) remains far from clear. We prospectively evaluated the role of serum and cerebrospinal fluid (CSF) VEGF in TBM.</p><p><strong>Patients and methods: </strong>This prospective study was conducted at a tertiary care center in North India from January 2018 to June 2019. Consecutive drug-naive patients (n = 82) of TBM diagnosed on the basis of modified Ahuja's criteria were included in the study. The results were compared with 49 control subjects (n = 49). Serum and CSF VEGF were done in all the cases and controls. Follow-up serum VEGF levels were done in 34 patients after 3 months of completion of antitubercular therapy. The VEGF levels were estimated using the human VEGF enzyme-linked immunosorbent assay kit.</p><p><strong>Results: </strong>The mean age was 29.9 ± 13.1 years. The study group consisted of 33 (40.2%) men and 49 (59.8%) women. BACTEC MGIT960 was positive in 15 (18%) patients while multiplex tuberculosis polymerase chain reaction was positive in 73 (89%) patients. Levels of VEGF in serum and CSF of TBM patients were not elevated when compared to controls. There was no association between final outcome in TBM and decrease in serum levels of VEGF at follow-up.</p><p><strong>Conclusion: </strong>VEGF may not be playing a significant role in the pathogenesis of TBM. Future studies with larger sample size may clarify the status of VEGF further in TBM.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41123029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Citicoline on the Barthel Index: Severe and moderate brain injury.","authors":"Mehdi Mahmoodkhani, Bahram Aminmansour, Mehdi Shafiei, Mohammadreza Hasas, Donya Sheibani Tehrani","doi":"10.4103/ijp.ijp_570_21","DOIUrl":"10.4103/ijp.ijp_570_21","url":null,"abstract":"<p><strong>Introduction: </strong>Traumatic brain injury (TBI) is a paramount factor in mortality and morbidity. The clinical trials conducted to investigate the efficacy of neuroprotective agents, such as citicoline, as a therapeutic alternative for TBI have presented divergent findings. Therefore, this study aimed to evaluate and compare citicoline's effect on the Barthel Index in patients with severe and moderate brain injury.</p><p><strong>Materials and methods: </strong>The study is a randomized clinical trial. Patients in the case group (35 patients) were treated with citicoline and the control group (34 patients) received a placebo. Data were analyzed using SPSS 16 software.</p><p><strong>Results: </strong>The results showed that changes in the Glasgow Coma Scale, changes in quadriceps muscle force score, Barthel Index score changes, achieving the status without intubation, and spontaneous breathing in patients treated with citicoline were not a statistically significant difference in the two groups (P > 0.05).</p><p><strong>Conclusion: </strong>Findings revealed that citicoline did not impact the recovery process of severe and moderate TBI patients.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41122079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacovigilance in the medical education: In UG curriculum where do we stand? What can be done?","authors":"Shiva Murthy Nanjundappa, Pratibha Durgesh Nadig, M K Jayanti, R M Veena, G N Manjunath","doi":"10.4103/ijp.ijp_145_23","DOIUrl":"10.4103/ijp.ijp_145_23","url":null,"abstract":"","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41138649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential use of <i>Balanophora latisepala</i> (V. Tiegh.) Lec. extract for the treatment of diabetes.","authors":"Nguyen Trong Hong Phuc, Nguyen Thi Yen Lan, Nguyen Van Ay","doi":"10.4103/ijp.ijp_253_23","DOIUrl":"10.4103/ijp.ijp_253_23","url":null,"abstract":"<p><strong>Introduction: </strong>Balanophora latisepala (BL) is a chlorophyll-free and obligate parasitic plant found across mountainous areas of An Giang, Vietnam. This study was conducted to evaluate the effectiveness of extracts from BL, herbs mentioned in many traditional medicines in the treatment of diabetes, on laboratory mice.</p><p><strong>Materials and methods: </strong>The effects of BL aqueous, methanol, and ethanol extracts on the blood glucose levels, hematological indices, liver enzymes, and pancreatic tissue structure of normal, glucose-tolerant mice, and diabetic mice treated with streptozotocin (STZ) were assessed. Mice were orally administered extracts at a concentration of 500 mg/kg.</p><p><strong>Results and discussion: </strong>The aqueous and ethanol extracts did not affect the blood glucose levels of healthy and glucose-tolerant mice (P > 0.05). The methanol extract reduced the blood glucose of healthy mice (P < 0.05) but did not affect the blood glucose of glucose-tolerant mice 3 h after administration (P > 0.05). When taking the methanol and ethanol extracts, the diabetic mice experienced a 45.67% and a 40.33% decrease in blood glucose levels after 21 days of research, respectively. Aqueous extract and gliclazide (10 mg/kg) showed no effect on reducing blood glucose levels in diabetic mice over the 21 days of the study. Both methanol and ethanol extracts were effective in regulating liver enzyme levels in diabetic mice. In both untreated and treated diabetic mice, pancreatic islet structures were degraded with the appearance of gaps resulting from β-cell degeneration.</p><p><strong>Conclusion: </strong>This implies that ethanol extracts have potential applications in regulating blood glucose levels.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41113817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of the National Ethics Committee Registry for Biomedical and Health Research in India: Stepping up to safeguard the ethical aspect of research involving human participants.","authors":"Balu Venugopal, Anu Nagar, Yogesh Kumar, Sujata Sinha","doi":"10.4103/ijp.ijp_216_22","DOIUrl":"10.4103/ijp.ijp_216_22","url":null,"abstract":"<p><p>As notified in the New Drugs and Clinical Trials Rules 2019, ethics committees (ECs), intending to review and oversee the conduct of Biomedical and Health Research (BHR) shall be required to register with the authority designated by the Central Government in the Ministry of Health and Family Welfare, Department of Health Research (DHR). The entire process of receiving and processing such applications is done online through the Naitik portal. Vide these rules, it has become mandatory for all institutions/entities whether publicly or privately conducting or intending to conduct BHR involving the human participants, to get their EC, registered with the DHR. A status report of the functioning of the National Ethics Registry and an analysis of ECs registered with the DHR are presented in this manuscript. A workflow of the processing involved in EC registration is given with sectorial segregation, and analysis of data on ECs across the country is made for the dissemination and information. This article elaborates on the registration requirements and process of the EC registry with the necessity of being registered with the DHR. 2100 login requests and more than 1560 applications for registration have been received; private hospitals and medical colleges have been the front-runner in getting their organization registered, and organizations in the commercial sector are faring better in terms of EC registration. Further dissemination and outreach efforts have to be made to draw the attention of various stakeholders regarding this requirement and thereby ensuring that all ECs in the country are registered with the DHR.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41132750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effects of ginsenosides in cisplatin-induced kidney injury: A systematic review, meta-analysis.","authors":"Xinyi Luo, Dengpiao Xie, Ziwei Chen, Qing Ji","doi":"10.4103/ijp.ijp_251_23","DOIUrl":"10.4103/ijp.ijp_251_23","url":null,"abstract":"<p><p>Although evidence suggests ginsenosides, the primary active and distinctive components of ginseng, have beneficial effects in cisplatin-induced nephrotoxicity, their efficacy and protective mechanisms remain unclear. The aim of the current meta-analysis is to study the effectiveness and mechanisms of ginsenosides in a model of nephrotoxicity induced by cisplatin. Preclinical investigations were conducted in the search of various databases including Medline, Web of Science, Google, CNKI, Embase, and the Wanfang database. 12 studies with 216 animals were included in this review. Stata 15.0 and RevMan 5.3 were used for statistical analyses. The pooled results showed that ginsenosides significantly improved kidney function, and inhibited histological damage. The protective mechanism of ginsenosides is associated with its antioxidative stress, anti-inflammation, anti-apoptosis, and anti-autophagy. The results of our study indicate that ginsenosides have the potential to mitigate nephrotoxicity induced by cisplatin through the modulation of various targets and pathways. Consequently, ginsenosides hold promise as therapeutic agents for the clinical management and prevention of cisplatin-induced nephrotoxicity.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.","authors":"Veneta Simon, Aathira Viswam, Pallavi Sarah Alexander, Emmanuel James, S Sudhindran","doi":"10.4103/ijp.ijp_762_20","DOIUrl":"10.4103/ijp.ijp_762_20","url":null,"abstract":"<p><strong>Objectives: </strong>Our study aimed to evaluate the real-world data on renal and neurological adverse effects and effectiveness of colistimethate sodium (CMS) and polymyxin B (PMB).</p><p><strong>Materials and methods: </strong>An observational prospective study was performed on inpatients receiving CMS and PMB for multidrug-resistant Gram-negative bacterial infections. CMS dose was titrated to renal function, and serum creatinine was assessed daily. The incidence of nephrotoxicity, the primary outcome, was evaluated based on an increase in serum creatinine from baseline as well as by the Risk, Injury, Failure, Loss of kidney function, and End-stage renal disease criteria. Neurological adverse effects were assessed based on clinical signs and symptoms, and the causality and severity were assessed by the Naranjo scale and modified Hartwig-Siegel scale, respectively. The effectiveness of polymyxin therapy was ascertained by a composite of microbiological eradication of causative bacteria and achievement of clinical cure. Thirty-day all-cause mortality was also determined.</p><p><strong>Results: </strong>Between CMS and PMB, the incidence of nephrotoxicity (59.3% vs. 55.6%, P = 0.653) or neurotoxicity (8.3% vs. 5.6%, P = 0.525) did not significantly differ. However, reversal of nephrotoxicity was significantly more with patients receiving CMS than PMB (48.4% vs. 23.3%, P = 0.021). Favorable clinical outcomes (67.6% vs. 37%, P < 0.001) and microbiological eradication of causative bacteria (73.1% vs. 46.3%, P = 0.001) were significantly more with CMS than PMB. Patients treated with CMS had lower all-cause mortality than those with PMB treatment (19.4% vs. 42.6%, P = 0.002).</p><p><strong>Conclusion: </strong>There is no significant difference in the incidence of renal and neurotoxic adverse effects between CMS and PMB when CMS is administered following renal dose modification. CMS shows better effectiveness and lower mortality compared to PMB.</p>","PeriodicalId":13490,"journal":{"name":"Indian Journal of Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41124795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}